BioSpace.com

Biotech and Pharmaceutical
News & Jobs
Search the Site
 
   
Biotechnology and Pharmaceutical Channel Medical Device and Diagnostics Channel Clinical Research Channel BioSpace Collaborative    Job Seekers:  Register | Login          Employers:  Register | Login  

NEWSLETTERS
Free Newsletters
Archive
My Subscriptions

NEWS
News by Subject
News by Disease
News by Date
PLoS
Search News
Post Your News
JoVE

CAREER NETWORK
Job Seeker Login
Most Recent Jobs
Browse Biotech Jobs
Search Jobs
Post Resume
Career Fairs
Career Resources
For Employers

HOTBEDS
Regional News
US & Canada
  Biotech Bay
  Biotech Beach
  Genetown
  Pharm Country
  BioCapital
  BioMidwest
  Bio NC
  BioForest
  Southern Pharm
  BioCanada East
  US Device
Europe
Asia

DIVERSITY

INVESTOR
Market Summary
News
IPOs

PROFILES
Company Profiles

START UPS
Companies
Events

INTELLIGENCE
Research Store

INDUSTRY EVENTS
Biotech Events
Post an Event
RESOURCES
Real Estate
Business Opportunities

 News | News By Subject | News by Disease News By Date | Search News
eNewsletter Signup
Miles
Km80.5

   

Haemacure Corporation (HAE) Files Notice of Intention to Make a Proposal to Creditors


1/11/2010 6:35:48 AM

Bookmark and Share

MONTREAL, Jan. 11 /PRNewswire-FirstCall/ - Haemacure Corporation announces that it has filed a notice of intention to make a proposal to its creditors under the Bankruptcy and Insolvency Act (Canada) and that its wholly-owned U.S. subsidiary sought court protection under Chapter 11 in the United States. The filings were made after the close of markets on Friday, January 8, 2010.

Haemacure's Board of Directors authorized these measures in light of Haemacure's financial condition and its inability to raise financing. The Board of Directors considers these measures to be in the best interests of Haemacure, its shareholders and creditors. The Board made this decision after thorough consultation with its professional advisors, both in Canada and the United States, and extensive consideration of all possible alternatives. The terms and conditions of the proposal to the creditors have not yet been determined by Haemacure.

Angiotech Pharmaceuticals, Inc., Haemacure's secured creditor, has agreed to provide financing to Haemacure in order to fund the insolvency proceedings and Haemacure's day-to-day operations, up to a maximum amount of US$1 million. The funds will be disbursed in accordance with a schedule agreed to by Haemacure and Angiotech.

Haemacure also announces that Mr. Marc Paquin has resigned as a director of Haemacure and no longer holds any position with Haemacure or its wholly-owned U.S. subsidiary. Mr. Paquin was previously President of Haemacure and a director and officer of the subsidiary company.

Read at BioSpace.com

   

ADD TO DEL.ICIO.US    ADD TO DIGG    ADD TO FURL    ADD TO STUMBLEUPON    ADD TO TECHNORATI FAVORITES